Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Aterian Inc (ATER) Price & Performance

AbCellera Biologics IncTrade
Aterian IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Aterian Inc — how do they compare? AbCellera Biologics Inc trades at $9.03 (market cap $2.85B), while Aterian Inc trades at $0.48 (market cap $5.22M). The key difference: AbCellera Biologics Inc is far larger — about 546× Aterian Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.

ABCLATER
Market Cap
$2.85B$5.22M
Sector
HealthConsumer Cyclical
52-Week High
$9.76$1.39
52-Week Low
$2.78$0.36
Enterprise Value
$2.45B$5.80M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Aterian Inc

Aterian (ATER) trades at $0.4934, up 7.03% in the last 24 hours, with a bearish technical signal overall. The company reported revenue of $68.98 million in 2025 but a net loss of $18.98 million, showing negative margins despite recent earnings beats. Recent news highlights a pending asset sale vote that could return $0.85–$1.14 per share to stockholders, creating near-term event-driven volatility.

The outlook hinges on the asset sale outcome, offering potential shareholder returns but also signaling business contraction. Risks include persistent cash burn, declining revenue, and high negative equity. Analysts are split 50/50 buy/hold, reflecting uncertainty amid restructuring efforts.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Aterian Inc

Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.

Read more on ATER